The FDA approved clobetasol propionate ophthalmic suspension 0.05% for the treatment of inflammation and pain after ocular surgery, according to a press release from Formosa Pharmaceuticals and AimMax Therapeutics.
“We believe ophthalmologists will be enthusiastic at having a new tool (first new steroid in the indication in more than 15 years) to address the aftereffects of ocular surgery,” Erick Co, president and CEO of Formosa, told Healio. “Through a commissioned [key opinion leader] survey, we observed that the dosing regimen (twice daily for 14 days) provided the most